Definium Therapeutics, Inc. (DFTX)
38.81
+0.13
(+0.34%)
USD |
NASDAQ |
Sep 18, 16:00
38.67
-0.14
(-0.36%)
After-Hours: 20:00
Definium Therapeutics Shares Outstanding (Quarterly) : 134.37M for June 30, 2026
Shares Outstanding (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shares Outstanding (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 134.37M |
| March 31, 2026 | 104.04M |
| December 31, 2025 | 98.78M |
| September 30, 2025 | 76.77M |
| June 30, 2025 | 75.80M |
| March 31, 2025 | 75.51M |
| December 31, 2024 | 75.10M |
| September 30, 2024 | 81.59M |
| June 30, 2024 | 72.08M |
| March 31, 2024 | 71.16M |
| December 31, 2023 | 41.10M |
| September 30, 2023 | 40.09M |
| June 30, 2023 | 38.81M |
| March 31, 2023 | 37.98M |
| December 31, 2022 | 37.98M |
| September 30, 2022 | 37.54M |
| June 30, 2022 | 28.45M |
| March 31, 2022 | 28.16M |
| December 31, 2021 | 28.13M |
| Date | Value |
|---|---|
| September 30, 2021 | 28.08M |
| June 30, 2021 | 27.82M |
| March 31, 2021 | 27.04M |
| December 31, 2020 | 24.08M |
| September 30, 2020 | 18.75M |
| June 30, 2020 | 18.71M |
| March 31, 2020 | 16.84M |
| August 31, 2019 | 0.4055M |
| May 31, 2019 | 0.4055M |
| February 28, 2019 | 0.4055M |
| November 30, 2018 | 0.3538M |
| August 31, 2018 | 0.3497M |
| May 31, 2018 | 0.3122M |
| February 28, 2018 | 0.3122M |
| November 30, 2017 | 0.3122M |
| August 31, 2017 | 0.308M |
| May 31, 2017 | 0.308M |
| February 28, 2017 | 0.2766M |
| November 30, 2016 | 0.2215M |
Shares Outstanding Definition
The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.
Shares Outstanding (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shares Outstanding (Quarterly) Benchmarks
| Enliven Therapeutics, Inc. | 73.25M |
| Cocrystal Pharma, Inc. | 13.79M |
| CNBX Pharmaceuticals, Inc. | 1.476B |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 65.30M |